Fever News and Research

RSS

Four mild forms of adenovirus cases at Voorhees Pediatric Facility under control and no new cases reported

Voorhees Pediatric Facility, a pediatric special care nursing facility located in Voorhees, New Jersey, has had four patients with chronic lung disease contract a mild form of adenovirus.

2 Nov 2018

Rubella eliminated from Australia confirms WHO

The World Health Organization (WHO) has confirmed that Australia has managed to eliminate the viral infection rubella from its population. This is a significant achievement on part of the country’s healthcare system. WHO defines elimination of a disease as “reduction to zero of the incidence of infection caused by a specific agent in a defined geographical area”.

2 Nov 2018

Measles can be deadly for people with weakened immune systems

Last year, a 26-year-old man receiving treatment for leukemia went to a Swiss hospital's emergency room with a fever, a sore throat, and a cough, and was admitted. His condition worsened, and 17 days later, he died from severe complications of measles.

1 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Researchers cross-reference historical divergence of Aedes aegypti populations

The BioScience Talks podcast features discussions of topical issues related to the biological sciences. Mosquito-borne diseases have plagued humanity for centuries, and a prolific offender has been Aedes aegypti, commonly known as the "yellow fever mosquito."

1 Nov 2018

Igenex launches advanced testing methods for rapid diagnosis of Bartonella infections

IGeneX is excited to announce the availability of their newly-developed, advanced testing methods to aid in the diagnosis of patients infected with Bartonella, an emerging epidemic with potentially disabling and life-threatening consequences.

30 Oct 2018

Monkeys infected with Zika virus points to a sylvatic transmission cycle

Zika virus has been detected in dead monkeys found in Brazil near São José do Rio Preto, São Paulo State, and Belo Horizonte, Minas Gerais.

30 Oct 2018

Urban mosquito control with help from scientists

Thanks to an innovative mosquito control approach developed at Rutgers University-New Brunswick, residents in several Maryland neighborhoods reduced populations of invasive Asian tiger mosquitoes by an impressive 76 percent, on average.

25 Oct 2018

Gene that makes some people susceptible to middle ear infections identified

Researchers at the University of Colorado Anschutz Medical Campus have found multiple genetic variants within the FUT2 gene that makes some people especially susceptible to middle ear infections.

25 Oct 2018

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

A new drug that works against flu has been developed and has been approved by the Food and Drug Administration (FDA) yesterday (24th October 2018). Until now the only drug available for flu is oseltamivir (Tamiflu) which is to be administered by two pills per day for five days after symptoms appear.

25 Oct 2018

Scientists engineer antiviral peptide that exploits Achilles' heel of Zika virus

Scientists at Nanyang Technological University, Singapore have engineered an antiviral peptide that exploits the Zika virus at its Achilles' heel - the viral membrane - hence stopping the virus from causing severe infections.

24 Oct 2018

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex's entire infectious disease vaccine platform.

24 Oct 2018

Simple technology prevents infectious disease outbreaks in low-resource settings

A pilot study in which healthcare workers in the Central African Republic used a smartphone app to transmit public health disease reports to health authorities demonstrates that this technique contributes to early detection and prevention of infectious diseases and outbreaks.

24 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics

Some bacterial pathogens, including those that cause strep throat and pneumonia, are able to create the components necessary to replicate their DNA without the usually required metal ions.

19 Oct 2018

Fever News and Research

Four mild forms of adenovirus cases at Voorhees Pediatric Facility under control and no new cases reported

Rubella eliminated from Australia confirms WHO

Measles can be deadly for people with weakened immune systems

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Researchers cross-reference historical divergence of Aedes aegypti populations

Igenex launches advanced testing methods for rapid diagnosis of Bartonella infections

Monkeys infected with Zika virus points to a sylvatic transmission cycle

Urban mosquito control with help from scientists

Gene that makes some people susceptible to middle ear infections identified

New flu drug Xofluza approved - FDA emphasizes importance of flu shots

Scientists engineer antiviral peptide that exploits Achilles' heel of Zika virus

Emergex completes toxicology testing on gold nanoparticle carrier system for vaccine platform

Simple technology prevents infectious disease outbreaks in low-resource settings

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Understanding of metal-free enzymes used by bacteria could lead to new effective antibiotics

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News